The Reducing REVISITS Study: A Cluster RCT

Summary

This type II hybrid effectiveness-implementation trial will concurrently study the comparative effectiveness of virtual vs. in-person COPD care transition programs implemented via virtual mentored implementation approaches with and without co-design methods.

The investigators will enroll up to 24 randomized sites (with a goal minimum of 16 sites) to:

* Deliver the COPD programs implemented via mentored support in collaboration with SHM Center for Quality Improvement.
* Compare the effectiveness and penetration of virtual versus in-person COPD care transition programs implemented along with mentoring support with or without co-design.

The investigators aim to determine which combined approach(es) is/are the most effective at implementing evidence-based COPD program interventions and decreasing COPD acute care revisits with the greatest overall impact and sustainability.

Conditions

• COPD
• COPD Exacerbation Acute

Interventions

BEHAVIORAL

COPD Transitions of Care Intervention Bundle: Virtual Interventions

The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. Virtual interventions included in the bundle may consist of: phone or e-consults for medication reconciliation, virtual teach-to-goal \[V-TTG\] or tele-TTG inhaler education, and post-discharge phone call communication and/or texts/ and/or electronic portal use, among others.

BEHAVIORAL

COPD Transitions of Care Intervention Bundle: In-Person Interventions

The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. In-person interventions include face-to-face general COPD education, inhaler education, medication reconciliation, post-discharge clinic visits, community health worker home visits, pulmonary rehabilitation, smoking cessation programs, among others.

Sponsors & Collaborators

• Society of Hospital Medicine

  collaborator OTHER

• Onda Collective

  collaborator UNKNOWN

• The Hospital Medicine Reengineering Network (HOMERuN)

  collaborator UNKNOWN

• COPD Foundation

  collaborator OTHER

• National Heart, Lung, and Blood Institute (NHLBI)

  collaborator NIH

• University of Chicago

  lead OTHER

Principal Investigators

• Valerie Press · University of Chicago

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Model

FACTORIAL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-02-15

Primary Completion

2026-03-31

Completion

2026-03-31

Countries

• United States

Study Locations